Validation of Treatment Patterns in Adults With Chronic Inflammatory Demyelinating Polyneuropathy in the United States Using Administrative Claims Datasets
Author(s)
Arvin-Berod C1, Blein C2, Guptill JG3, Gelinas D3, Barrera-Sierra SBS3, Ulla H4, Ward C5, Sato M6, Goyal A5
1argenx, Ghent, East Flanders, Belgium, 2argenx, Zwijnaarde, Belgium, 3Argenx, US, Boston, MA, USA, 4ZS Associates, Haryana, India, 5ZS Associates, New york, NY, USA, 6ZS Associates, New York, NY, USA
Presentation Documents
OBJECTIVES: In the United States (US), representation of payers (Commercial, Medicaid, Medicare, etc.) can differ across claims databases depending on their data source, potentially impacting real-world estimates such as treatment usage.
To evaluate external validity of treatment pattern results among patients with chronic inflammatory demyelinating polyneuropathy (CIDP) across 2 US claims datasets.METHODS: Two US-based claims datasets were utilized (dataset 1: Komodo Health closed claims, Jan 2016 – Dec 2020; dataset 2: Optum’s de-identified Market Clarity Data [Market Clarity] [Jan 2015 – Dec 2019]). Patients with CIDP were selected based on presence of: (1) ≥2 claims with CIDP diagnosis, ≥30-≤365 days apart (first considered as index date), (2) ≥1 nerve conduction test present either after the index date and before another CIDP diagnosis, or ≤90 days before the index date, and (3) continuous enrollment with a minimum ±1 year pre- and post-index date. Insurance was assessed at index date, and CIDP treatments used were evaluated during year 1 post-index date.
RESULTS: In dataset 1, 3409 patients were identified with CIDP during the study period, with 49% using commercial insurance, 27% using Medicare, and 13% using Medicaid. The most common CIDP treatment in year 1 was immunoglobulins (IG, used by 53% of patients), while 19% were untreated. In dataset 2, 1290 patients were identified with CIDP during the study period, with 58% using commercial insurance, 26% using Medicare, and 5% using Medicaid. The most common CIDP treatment in year 1 was immunoglobulins (IG, used by 54% of patients), while 21% were untreated.
CONCLUSIONS:
Across 2 US claims datasets with varied representation of patients and payers, year 1 treatment patterns in CIDP were consistent. IG was the most common treatment among those receiving CIDP treatment, with a considerable proportion of patients observed to be untreated for CIDP across both datasets.Conference/Value in Health Info
Value in Health, Volume 27, Issue 6, S1 (June 2024)
Code
RWD124
Topic
Real World Data & Information Systems, Study Approaches
Topic Subcategory
Health & Insurance Records Systems
Disease
Drugs, Neurological Disorders, Rare & Orphan Diseases